These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 12563672

  • 1. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.
    Cohen SB, Woolley JM, Chan W, Anakinra 960180 Study Group.
    J Rheumatol; 2003 Feb; 30(2):225-31. PubMed ID: 12563672
    [Abstract] [Full Text] [Related]

  • 2. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 3. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B.
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [Abstract] [Full Text] [Related]

  • 4. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

  • 6. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B, Leflunomide Rheumatoid Arthritis Investigators Groups.
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [Abstract] [Full Text] [Related]

  • 7. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 8. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G.
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [Abstract] [Full Text] [Related]

  • 9. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [Abstract] [Full Text] [Related]

  • 10. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J, 990757 Study Group.
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, 20000223 Study Group.
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [Abstract] [Full Text] [Related]

  • 12. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M, Holmes T, Schettler JD, Fries JF.
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [Abstract] [Full Text] [Related]

  • 13. Revalidation of the original Cedars-Sinai health-related quality of life in rheumatoid arthritis questionnaire.
    Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, Weisman M.
    J Rheumatol; 2006 Feb; 33(2):256-62. PubMed ID: 16465655
    [Abstract] [Full Text] [Related]

  • 14. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 15. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 16. Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis.
    Taylor WJ, McPherson KM.
    Arthritis Rheum; 2007 Jun 15; 57(5):723-9. PubMed ID: 17530670
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
    Karanikolas G, Charalambopoulos D, Vaiopoulos G, Andrianakos A, Rapti A, Karras D, Kaskani E, Sfikakis PP.
    Rheumatology (Oxford); 2008 Sep 15; 47(9):1384-8. PubMed ID: 18603660
    [Abstract] [Full Text] [Related]

  • 18. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
    J Rheumatol; 2008 Jan 15; 35(1):20-30. PubMed ID: 18050385
    [Abstract] [Full Text] [Related]

  • 19. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.
    Ann Rheum Dis; 2006 Mar 15; 65(3):328-34. PubMed ID: 16079172
    [Abstract] [Full Text] [Related]

  • 20. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction.
    Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A.
    J Rheumatol; 2011 Nov 15; 38(11):2461-5. PubMed ID: 21885498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.